Open AccessEnhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors
Author(s) -
Seema Gupta,
Abdullah Farooque,
Jawahar Singh Adhikari,
Saurabh Singh,
Bilikere S. Dwarakanath
Publication year - 2009
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.55135
Subject(s) - in vivo , radiation therapy , toxicity , medicine , cancer research , drug , pharmacology , clinical trial , cancer , 2 deoxy d glucose , glioma , oncology , biology , microbiology and biotechnology
The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.